ZyVersa Therapeutics (ZVSA) highlights data from an article published in the peer-reviewed International Journal of Nanomedicine titled Small Intestinal Endocrine Cell Derived Exosomal ACE2 Protects Islet beta-Cell Function by Inhibiting the Activation of NLRP3 Inflammasome and Reducing beta-Cell Pyroptosis. Through investigation on how exosomes derived from gut microbiota can transport signals to remotely regulate pancreatic islet beta-cell function, the researchers documented that: Inflammasome-driven inflammation resulted in severely damaged pancreatic islets. Damaged Islets demonstrated disrupted cellular arrangement and visible vascular thickening, leading to islet cell loss and metabolic dysfunction. Inflammasome inhibition reduced the inflammation and pancreatic islet damage, and attenuated the metabolic dysfunction.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZVSA:
- ZyVersa Therapeutics’ Shareholder Approvals and Director Elections
- ZyVersa highlights review article on inflammasome-induced inflammation
- ZyVersa Therapeutics announces publication of data on obesity, neuroinflammation
- ZyVersa Therapeutics CEO highlights obesity development plans for IC 100
- ZyVersa Therapeutics forms Scientific Advisory Board
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
